Trial Profile
Phase II Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Sep 2022
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary)
- Indications Smoldering multiple myeloma
- Focus Therapeutic Use
- 18 Sep 2022 Planned End Date changed from 7 Jan 2025 to 8 Apr 2025.
- 18 Sep 2022 Planned primary completion date changed from 7 Jan 2025 to 8 Apr 2025.
- 15 Mar 2022 Planned End Date changed from 1 Apr 2024 to 7 Jan 2025.